News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cell>Point Presents Phase 2 Clinical Trial Results Comparing its 99mTc-EC-G SPECT Cancer Imaging Agent to FDG PET at Society of Nuclear Medicine Annual Meeting June 7, 2011


6/6/2011 10:34:08 AM

CENTENNIAL, Colo.--(BUSINESS WIRE)--Cell>Point announced today that it will present Phase 2 clinical trial results for its cancer molecular imaging agent, 99mTc-EC-G (99mTechnetium-EthylenediCysteine-n-acetyl-Glucosamine), used to diagnose and stage patients with Non-Small Cell Lung Cancer (NSCLC) at the 2011 Society of Nuclear Medicine Annual Meeting on June 7, 2011.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES